# US 2025/0084478 A1 · Multivalent binding compositions with reactive groups

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084478 A1
- Document ID: US20250084478A1
- Status: Published application
- Kind: A1
- Application number: 18/957,338
- Filed: 2024-11-22
- Published: 2025-03-13
- Earliest claimed: 2022-04-07
- Assignees: Element Biosciences, Inc.
- Applicants: Element Biosciences, Inc.
- Inventors: MICHAEL PREVITE; MARK AMBROSO; TYLER LOPEZ; MICHAEL KLEIN; VIRGINIA SAADE; MATTHEW KELLINGER
- Web page: https://patentgrep.com/patent/US20250084478A1

## CPC

- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C12Y 207/07007: DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides nucleotide conjugates each configured to include a core attached to multiple nucleotide-arms, where the nucleotide-arms are modular and comprise (i) a core attachment moiety, (ii) a spacer, (iii) a linker, and (iv) a nucleotide unit. The nucleotide unit of each nucleotide-arm can bind a polymerase which is complexed with a nucleic acid template and nucleic acid primer. The nucleotide unit can bind the 3′ end of the primer at a position that is opposite a complementary nucleotide in the template strand. Under suitable conditions, the nucleotide unit of the nucleotide conjugates binds the primer strand but does not undergo polymerase-catalyzed incorporation. The binding event can be detected, and the specific base of the nucleotide unit can be identified. The nucleotide conjugates described herein are useful for nucleic acid sequencing methods, particularly for massively parallel sequencing methods employed for next gen sequencing platforms.

## Claims

### Claim 1

A nucleotide conjugate, comprising:
at least two nucleotide arms, wherein a nucleotide arm of the at least two nucleotide arms comprises a linker selected from:

### Claim 2 (depends on 1)

The nucleotide conjugate of claim 1, further comprising a common core.

### Claim 3 (depends on 2)

The nucleotide conjugate of claim 2, further comprising a spacer, wherein the spacer is coupled to the common core, and wherein the linker is coupled to the spacer.

### Claim 4 (depends on 1)

The nucleotide conjugate of claim 1, further comprising a nucleotide, wherein the nucleotide is coupled to the linker.

### Claim 5 (depends on 4)

The nucleotide conjugate of claim 4, wherein the nucleotide is a detectable nucleotide.

### Claim 6 (depends on 1)

The nucleotide conjugate of claim 1, wherein the linker is optionally substituted with a reactive group selected from the group consisting of an alkyl group, alkenyl group, alkynyl group, allyl group, aryl group, benzyl group, azide group, amine group, amide group, keto group, isocyanate group, phosphate group, thiol group, disulfide group, carbonate group, urea group, or silyl group.

### Claim 7

A method for processing a nucleic acid molecule, the method comprising:
(a) introducing a synthetic polypeptide and a nucleotide conjugate to a nucleic acid sequence hybridized to a primer nucleic acid sequence under conditions sufficient to form a binding complex comprising the synthetic polypeptide, the nucleotide conjugate and the nucleic acid sequence,
wherein a nucleotide of the nucleotide conjugate is complementary to a nucleotide of the nucleic acid sequence, and
wherein the nucleotide-conjugate comprises at least two nucleotide arms, wherein a nucleotide arm of the at least two nucleotide arms comprises:
(i) a common core;
(ii) a spacer, wherein the spacer is coupled to the common core;
(iii) a linker, wherein the linker is coupled to the spacer; and
(iv) the nucleotide, wherein the nucleotide is coupled to the linker;
wherein the linker is selected from:
and
(b) detecting the binding complex to identify the nucleotide of the nucleic acid sequence.

### Claim 8 (depends on 7)

The method of claim 7, wherein the linker is optionally substituted with a reactive group selected from the group consisting of an alkyl group, alkenyl group, alkynyl group, allyl group, aryl group, benzyl group, azide group, amine group, amide group, keto group, isocyanate group, phosphate group, thiol group, disulfide group, carbonate group, urea group, or silyl group.

### Claim 9 (depends on 7)

The method of claim 7, wherein the nucleotide is a detectable nucleotide.

### Claim 10 (depends on 7)

The method of claim 7, wherein the at least two nucleotide arms comprises 3 to 20 nucleotide arms.

### Claim 11 (depends on 7)

The method of claim 7, wherein the common core comprises streptavidin or avidin.

### Claim 12 (depends on 7)

The method of claim 7, wherein the nucleotide conjugate further comprises a core attachment moiety, wherein the core attachment moiety is coupled to the common core and the spacer.

### Claim 13 (depends on 12)

The method of claim 12, wherein the core attachment moiety comprises biotin.

### Claim 14 (depends on 7)

The method of claim 7, wherein the nucleotide comprises a blocking group.

### Claim 15 (depends on 14)

The method of claim 14, wherein the blocking group is coupled directly or indirectly to a 3′ carbon of the sugar of the detectable nucleotide, and wherein the blocking group is removable from the detectable nucleotide to generate a hydroxyl group on the 3′ carbon.

### Claim 16 (depends on 14)

The method of claim 14, wherein the blocking group comprises a 3′-O-azidomethyl group, 3′-O-methyl group, a 3′-O-alkyl hydroxylamino group, a 3′-phosphorothioate group, a 3′-O-malonyl group, or a 3′-O-benzyl group.

### Claim 17 (depends on 14)

The method of claim 14, wherein the blocking group comprises a 3′-O-azidomethyl group.

### Claim 18 (depends on 7)

The method of claim 7, wherein the nucleotide comprises a label coupled thereto directly or indirectly.

### Claim 19 (depends on 7)

The method of claim 7, wherein a 3′ terminal nucleotide of the primer nucleic acid sequence comprises a blocking group.

### Claim 20 (depends on 19)

The method of claim 19, wherein the blocking group comprises a 3′-O-azidomethyl group, 3′-O-methyl group, a 3′-O-alkyl hydroxylamino group, a 3′-phosphorothioate group, a 3′-O-malonyl group, or a 3′-O-benzyl group.

### Claim 21 (depends on 7)

The method of claim 7, wherein (b) does not comprise incorporating the detectable nucleotide into a 3′ terminus of the primer nucleic acid sequence.

### Claim 22 (depends on 7)

The method of claim 7, further comprising incorporating the detectable nucleotide into a 3′ terminus of the primer nucleic acid sequence.

### Claim 23 (depends on 7)

The method of claim 7, wherein the binding complex is a multivalent binding complex comprising at least two of the synthetic polypeptide, at least two of the detectable nucleotide, and at least two of the nucleic acid sequence.

### Claim 24 (depends on 7)

The method of claim 7, wherein the synthetic polypeptide has an amino acid sequence that has at least 85% sequence identity to SEQ ID NO: 391.

### Claim 25 (depends on 24)

The method of claim 24, wherein the synthetic polypeptide comprises a D141A mutation with reference to SEQ ID NO: 391.

### Claim 26 (depends on 24)

The method of claim 24, wherein the synthetic polypeptide comprises an E143A mutation with reference to SEQ ID NO: 391.

### Claim 27 (depends on 24)

The method of claim 24, wherein the synthetic polypeptide comprises a D141A mutation and an E143A mutation with reference to SEQ ID NO: 391.

### Claim 28 (depends on 24)

The method of claim 24, wherein the amino acid sequence further comprises a Y410A mutation, a L409S mutation, a Y261A mutation, a P411G mutation, an F406I mutation, a P411A mutation, a Y7A mutation, a Y493I mutation, a Y493T mutation, a V513I mutation, a L409A mutation, an A485S mutation, a Y410G mutation, an I521H mutation, or a K507L mutation, or any combination thereof, with reference to SEQ ID No: 391.

### Claim 29 (depends on 24)

The method of claim 24, wherein the amino acid sequence further comprises:
(a) a Y410A mutation, with reference to SEQ ID No: 391;
(b) a L409S mutation, a Y410A mutation, and a Y261A mutation, with reference to SEQ ID No: 391;
(c) a L409S mutation, a Y410A mutation, a P411G mutation, and a Y261A mutation, with reference to SEQ ID No: 391;
(d) a Y261A mutation, an F406I mutation, a L409S mutation, a Y410A mutation, and a P411A mutation, with reference to SEQ ID No: 391;
(e) a Y7A mutation, a Y261A mutation, and a Y410A mutation, with reference to SEQ ID No: 391;
(f) a Y261A mutation, a Y410A mutation, and a Y493I mutation, with reference to SEQ ID No: 391;
(g) a Y261A mutation, a Y410A mutation, and a Y493T mutation, with reference to SEQ ID No: 391;
(h) a Y261A mutation, a Y410A mutation, and a V513I mutation, with reference to SEQ ID No: 391;
(i) a Y7A mutation, a Y261A mutation, a L409S mutation, and a Y410A mutation, with reference to SEQ ID No: 391;
(j) a Y261A mutation, a L409A mutation, a Y410A mutation, and a P41 TA mutation, with reference to SEQ ID No: 391;
(k) a Y261A mutation, a L409S mutation, a Y410A mutation, and a P411G mutation, with reference to SEQ ID No: 391;
(l) a Y261A mutation, a L409S mutation, and a Y410A mutation, with reference to SEQ ID No: 391;
(m) a Y261A mutation, a L409S mutation, and a Y410G mutation, with reference to SEQ ID No: 391;
(n) a Y261A mutation, a L409A mutation, a Y410A mutation, a P411A mutation, and an A485S mutation, with reference to SEQ ID No: 391;
(o) a Y261A mutation, a L409S mutation, a Y410A mutation, a P411G mutation, and an A485S mutation, with reference to SEQ ID No: 391;
(p) a Y261A mutation, a L409S mutation, a Y410A mutation, and an A485S mutation, with reference to SEQ ID No: 391;
(q) a Y261A mutation, a L409S mutation, a Y410G mutation, and an A485S mutation, with reference to SEQ ID No: 391;
(r) a Y261A mutation, a L409A mutation, a Y410A mutation, a P411A mutation, and an I521H mutation, with reference to SEQ ID No: 391;
(s) a Y261A mutation, a L409S mutation, a Y410A mutation, a P411G mutation, and an I521H mutation, with reference to SEQ ID No: 391;
(t) a Y261A mutation, a L409S mutation, a Y410A mutation, and an 1521H mutation, with reference to SEQ ID No: 391;
(u) a Y261A mutation, a L409S mutation, a Y410G mutation, and an 1521H mutation, with reference to SEQ ID No: 391; or
(v) a Y261A mutation, a L409S mutation, a Y410A mutation, an A485S mutation, a K507L mutation, and an I521H mutation, with reference to SEQ ID No: 391.

### Claim 30 (depends on 24)

The method of claim 24, wherein the amino acid sequence has at least 90% sequence identity to SEQ ID NO: 391.

### Claim 31 (depends on 24)

The method of claim 24, wherein the amino acid sequence has at least 99% sequence identity to SEQ ID NO: 391.

### Claim 32 (depends on 24)

The method of claim 24, wherein the amino acid sequence comprises any one of SEQ ID NOs: 392-413.
